98
Participants
Start Date
January 31, 2013
Primary Completion Date
September 30, 2014
Study Completion Date
May 31, 2015
Tolvaptan
Tolvaptan (OPC-41061) is a benzazepine derivative synthesized by Otsuka Pharmaceutical Company, Ltd. Tolvaptan was approved for the treatment of specific forms of hyponatremia by the United States (US) Food and Drug Administration (FDA) in May 2009, the European Medicines Agency on Aug 2009, Japan (Oct 2010), China (Sep 2011) and Korea (Sep 2011). Tolvaptan was approved for the adjunct treatment of volume overload in heart failure by the Japanese Ministry of Health, Labour, and Welfare (MHLW) in Oct 2010. It is also being developed for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and for the treatment of hepatic edema.
conventional thearpy
conventional therapy with salt limitation ,et al
Beijing Ditan Hospital, Beijing
Peking University First Hospital, Beijing
Peking University People's Hospital, Beijing
Beijing Friendship Hospital, Capital Medical University, Beijing
Beijing Youan Hospital, Beijing
Shanghai Shuguang Hospital Affiliated with Shanghai University of Traditional Chinese Medicine, Shanghai
Zhongshan Hospital Fudan University, Shanghai
Shanghai Huashan Hospital, Shanghai
85 Militay Hospital, Shanghai
Shanghai Xinhua Hospital, Shanghai
Shanghai Renji Hospital, Beijing
Shanghai Putuo District Central Hospital, Shanghai
Shanghai Changhai Hospital, Shanghai
Shanghai Public Health Clinical Center, Shanghai
The Third Affiliated Hospital of Sun Yat-sen University, Guangdong
302 Military Hospital Integrative Medicine, Beijing
302 Military Hospital Liver Failure Center, Beijing
Guangdong General Hospital, Guangdong
Zhujiang Hospital of Southern Medical University, Guangdong
Chinese University of Hong Kong
OTHER
Beijing Friendship Hospital
OTHER